Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ERC-1671 by ERC Belgium for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
ERC-1671 is under clinical development by ERC Belgium and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to...
Data Insights
ERC-1671 by ERC Belgium for Gliosarcoma: Likelihood of Approval
ERC-1671 is under clinical development by ERC Belgium and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II...